Valneva SE (NASDAQ:VALN) Short Interest Down 49.2% in April

Valneva SE (NASDAQ:VALN - Get Free Report) saw a large drop in short interest in April. As of April 15th, there was short interest totalling 9,900 shares, a drop of 49.2% from the March 31st total of 19,500 shares. Approximately 0.0% of the shares of the stock are short sold. Based on an average trading volume of 78,400 shares, the days-to-cover ratio is currently 0.1 days.

Institutional Trading of Valneva

A number of large investors have recently bought and sold shares of the business. Wells Fargo & Company MN boosted its position in shares of Valneva by 14.3% during the 4th quarter. Wells Fargo & Company MN now owns 246,766 shares of the company's stock valued at $1,079,000 after purchasing an additional 30,859 shares in the last quarter. ABC Arbitrage SA bought a new position in shares of Valneva during the 4th quarter worth approximately $84,000. Finally, GAMMA Investing LLC bought a new position in shares of Valneva during the 1st quarter worth approximately $94,000. 11.39% of the stock is currently owned by institutional investors and hedge funds.

Valneva Trading Up 0.4 %

Shares of Valneva stock traded up $0.03 during trading on Friday, hitting $6.41. The company's stock had a trading volume of 46,675 shares, compared to its average volume of 36,538. The stock has a market cap of $535.77 million, a price-to-earnings ratio of -49.54 and a beta of 1.85. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.78 and a quick ratio of 2.25. Valneva has a 52 week low of $3.62 and a 52 week high of $9.50. The stock has a 50-day moving average price of $6.82 and a two-hundred day moving average price of $5.72.

Valneva (NASDAQ:VALN - Get Free Report) last issued its quarterly earnings data on Thursday, March 20th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.32). The company had revenue of $56.48 million for the quarter, compared to the consensus estimate of $55.64 million. Valneva had a negative return on equity of 3.93% and a negative net margin of 4.35%. Equities research analysts anticipate that Valneva will post 0.13 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on VALN shares. HC Wainwright reaffirmed a "buy" rating and issued a $17.00 target price on shares of Valneva in a report on Tuesday, April 15th. Guggenheim dropped their price objective on shares of Valneva from $17.00 to $15.00 and set a "buy" rating for the company in a report on Monday, March 24th.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.